a
C
(
eritical groups within the population, provided the critical group
is small enough to be homogeneous with respect to age, diet and those
aspects of behavior that affect the doses received.
Such a group
should be representative of those individuals in the population
expected to receive the highest dose.
ICRP believes that it will
be reasonable to apply the appropriate dose limit for members of
the public to the mean dose of this group.
The inate variability within an apparently homogeneous group
"means that some members of ‘the critical group will receive doses
somewhat higher than the dose limit.
gen i,A
eet
.
tle
oe .
ey
« eR
Ie
~ tetoa
wat
wit ees
<9 ft
TL he ESnove
At the very low levels of
:
.
aa
lile
“3
a st
ee
oe,
272.
eee
'
=risk tnplied,the‘healéh” coneeeannee di
isLakedy to be minor whether
the dose limit is marginally or substantially exceeded.
tives,adhsimi tation‘of exposure.of whole -populations: is achieved partlyiceSo
“by Limiting the’ individual doses and partly by limiting the number
Padtagh ea Medes Decree os Satoh neva iss Boba ky Sate Teg et eadts
teste alTots
“of persons exposed. It is of the utmost importance toavoid actions
‘that may prove to be a seriovs hazard later, when correction may be
OE FF ec Guipossible or” costly: PEEVE Neko le ee al ine SoReal
The ICRP dose limits for individual members of the public are
in Table #.
tion is given.
no- threshold,
Using the linear dose-effect relationship and assuming
the ICRP indicates that an annual exposure of active
red marrow, averaged over each individual in the population, of 0.5
rem (corresponding to the annual dose limit for members of the public)
might at equilibrium lead to an increased incidence of leukemia, at
most, of about ten cases per year per million persons exposed.
The genetic dose to the population should be kept to the minimum
SN
‘
!
amount consistent with necessity and should certainly not exceed 5
~—
“~~
ney
No maximum "“somatically significant’ dose for a populea-